KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Short-term Investments (2016 - 2025)

Gilead Sciences (GILD) has disclosed Short-term Investments for 16 consecutive years, with $19.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments changed N/A year-over-year to $19.0 million, compared with a TTM value of $19.0 million through Sep 2025, changed N/A, and an annual FY2023 reading of $1.2 billion, up 21.17% over the prior year.
  • Short-term Investments was $19.0 million for Q3 2025 at Gilead Sciences, down from $69.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $1.6 billion in Q2 2021 and bottomed at $19.0 million in Q3 2025.
  • Average Short-term Investments over 4 years is $905.2 million, with a median of $1.1 billion recorded in 2022.
  • The sharpest move saw Short-term Investments plummeted 86.59% in 2021, then increased 21.17% in 2023.
  • Year by year, Short-term Investments stood at $1.2 billion in 2021, then dropped by 17.68% to $973.0 million in 2022, then rose by 21.17% to $1.2 billion in 2023, then plummeted by 98.39% to $19.0 million in 2025.
  • Business Quant data shows Short-term Investments for GILD at $19.0 million in Q3 2025, $69.0 million in Q2 2025, and $1.2 billion in Q4 2023.